Levofloxacin 1.5% concentration combats ocular pathogens

August 1, 2003

Fort Lauderdale, FL-Topical levofloxacin 1.5% (Santen), a new concentration of the drug in clinical development, achieves tear-fluid concentrations well above the reported minimum inhibitory concentrations (MIC) for the most common ocular pathogens, reported Tom R. Walters, MD, at the annual meeting of the Association for Research in Vision and Ophthalmology.